Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

986 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC.
Del Re M, Cucchiara F, Rofi E, Fontanelli L, Petrini I, Gri N, Pasquini G, Rizzo M, Gabelloni M, Belluomini L, Crucitta S, Ciampi R, Frassoldati A, Neri E, Porta C, Danesi R. Del Re M, et al. Among authors: porta c. Cancer Immunol Immunother. 2021 Jun;70(6):1667-1678. doi: 10.1007/s00262-020-02810-6. Epub 2020 Dec 14. Cancer Immunol Immunother. 2021. PMID: 33315149 Free PMC article.
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.
Passalacqua R, Buzio C, Buti S, Porta C, Labianca R, Pezzuolo D, Camisa R, Sabbatini R, Benecchi L, Messina C, Cengarle R, Vaglio A, Dalla Chiesa M, Tomasello G, Caminiti C. Passalacqua R, et al. Among authors: porta c. Cancer Immunol Immunother. 2010 Apr;59(4):553-61. doi: 10.1007/s00262-009-0773-9. Epub 2009 Sep 25. Cancer Immunol Immunother. 2010. PMID: 19779715 Free PMC article. Clinical Trial.
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
Porta C, Procopio G, Cartenì G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V, Bajetta E. Porta C, et al. BJU Int. 2011 Oct;108(8 Pt 2):E250-7. doi: 10.1111/j.1464-410X.2011.10186.x. Epub 2011 May 23. BJU Int. 2011. PMID: 21599821
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM, Wells C, Moreira R, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst DS, Rini BI, Yuasa T, Basappa NS, Kanesvaran R, Wood LA, Canil C, Kapoor A, Fu SYF, Choueiri TK, Heng DYC. Yip SM, et al. Among authors: porta c. Cancer. 2018 Sep 15;124(18):3677-3683. doi: 10.1002/cncr.31595. Epub 2018 Oct 11. Cancer. 2018. PMID: 30307610 Free article.
Targeting angiogenesis in metastatic renal cell carcinoma.
Canino C, Perrone L, Bosco E, Saltalamacchia G, Mosca A, Rizzo M, Porta C. Canino C, et al. Among authors: porta c. Expert Rev Anticancer Ther. 2019 Mar;19(3):245-257. doi: 10.1080/14737140.2019.1574574. Epub 2019 Feb 6. Expert Rev Anticancer Ther. 2019. PMID: 30678509 Review.
The effect of a treatment delay on outcome in metastatic renal cell carcinoma.
Iacovelli R, Galli L, De Giorgi U, Porta C, Nolè F, Zucali P, Sabbatini R, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Buti S, Massari F, Masini C, Ricotta R, Biasco E, Lolli C, Gri N, Verri E, Miggiano C, Vitale MG, Tortora G. Iacovelli R, et al. Among authors: porta c. Urol Oncol. 2019 Aug;37(8):529.e1-529.e7. doi: 10.1016/j.urolonc.2019.03.005. Epub 2019 Mar 29. Urol Oncol. 2019. PMID: 30935843
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
Verzoni E, Cartenì G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, Buti S, Rossetti S, Cognetti F, Rastelli F, Sobrero A, Turci D, Sternberg CN, Porta C, Cappuzzo F, Tortora G, Tassinari D, Panni S, Pazzola A, Surico G, Raimondi A, De Giorgi U, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program group. Verzoni E, et al. Among authors: porta c. J Immunother Cancer. 2019 Apr 3;7(1):99. doi: 10.1186/s40425-019-0579-z. J Immunother Cancer. 2019. PMID: 30944023 Free PMC article.
986 results